Rat |
Bone marrow |
MSC-CM |
1 ml (from 1 × 106 MSCs) |
Penile vein |
Radiation |
Rat |
Inhibit the apoptosis of SECs; inhibit histopathological changes |
Attenuate liver inflammation |
[79] |
Rat |
Bone marrow |
25-fold concentrated MSC-CM |
1 ml |
Penile vein |
50% RSLT |
Rat |
Attenuate liver injury; provide a survival benefit |
Reduce apoptosis of hepatocytes and SECs; reduce the secretion of proinflammatory cytokines; reduce the infiltration of neutrophils; activation of Kupffer cells |
[80] |
Mouse |
Bone marrow |
25-fold concentrated MSC-CM |
200 μl |
Tail vein |
TAA/CCl4
|
Mouse |
Rescue ALF mice; suppress fibrogenesis |
Downregulate the number of infiltrating macrophages; convert CD4+ T lymphocytes into anti-inflammatory Tregs and Th2 cells; facilitate HSC death |
[81] |
Human |
Tonsil |
20-fold concentrated MSC-CM |
200 μl |
Tail vein |
CCl4
|
Mouse |
Reduce liver fibrosis |
Attenuate liver inflammation |
[82] |
Mouse |
Bone marrow |
Exosomes |
10 μg |
Intravenous |
Con A |
Mouse |
Decrease the ALT level; decrease the scope of liver necrotic areas; decrease the extent of apoptosis; increase the proliferation of liver cells |
Activate anti-inflammation; activate Tregs |
[83] |
Human |
iPSCs |
Exosomes |
2.5 × 1012 particles |
Inferior vena cava |
Ischemia/reperfusion |
Mouse |
Decrease the histopathological scores and serum levels of aminotransferases |
Inhibit hepatocyte necrosis and sinusoidal congestion; upregulate hepatocyte proliferation |
[84] |
Human |
Umbilical cord |
Exosomes |
100 μg |
Tail vein |
D-GalN/LPS |
Mouse |
Repair damaged liver tissue; decrease serum levels of ALT and AST |
Reduce the activity of the NLRP3 inflammasome in macrophages |
[85] |
Human |
Menstrual blood |
Exosomes |
N/A |
Tail vein |
D-GalN/LPS |
Mouse |
Improve liver functions; inhibit hepatocyte apoptosis; increase survival rates |
Migrate into liver tissue; reduce the activation of MNCs; decrease the level of the apoptotic protein caspase-3 |
[86] |
Human |
Umbilical Cord |
Exosomes |
6.4 × 109 particles |
Tail vein |
CCl4
|
Mouse |
Decrease the rates of acute liver injury and liver fibrosis |
Inhibit oxidative stress; inhibit hepatocyte apoptosis |
[87] |
Human |
Bone marrow |
Exosomes |
250 mg |
Tail vein |
CCl4
|
Rat |
Alleviate liver fibrosis |
Inhibit HSC activation; activate the Wnt/β-catenin pathway |
[88] |
Human |
Umbilical cord |
25-fold concentrated MSC-CM |
7.2 ml |
Liver lobe |
CCl4
|
Mouse |
Ameliorate liver fibrosis; restore liver functions |
Inhibit EMT; protect against hepatocyte apoptosis |
[89] |
Mice |
Adipose tissue |
Exosomes |
400 μg |
Tail vein |
D-GalN/LPS |
Mouse |
Repair damaged liver tissue; decrease serum levels of ALT and AST |
Reduce the activation of TXNIP/NLRP3 in macrophages |
[90] |
Human |
Umbilical cord |
Exosomes |
8 mg/kg, 16 mg/kg, and 32 mg/kg |
Tail vein |
CCl4
|
Mouse |
Rescue ALF; increase survival rates |
Deliver GPX1; reduce oxidative stress; reduce apoptosis |
[91] |